Phase I study of CHOP [cyclophosphamide + doxorubicin + vincristine + prednisone] plus Campath [alemtuzumab] (C-CHOP) for the treatment of T-cell, null-cell, and NK cell lymphomas
Phase of Trial: Phase I
Latest Information Update: 21 Oct 2008
At a glance
- Drugs Alemtuzumab; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Non-Hodgkin's lymphoma; T cell lymphoma
- Focus Adverse reactions
- 21 Oct 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 19 Jul 2007 Status change from recruiting to in progress
- 22 Oct 2005 New trial record.